Mapping cancer research across Central and Eastern Europe, the Russian Federation and Central Asia: Implications for future national cancer control planning.

Cancer research is an essential part of national cancer control programmes, and the emerging economies of Central and Eastern Europe (CEE) and the Russian Federation and Central Asia (R-CA) (Commonwealth of Independent States) remain relatively understudied. Here, we map the cancer research activity from the 29 countries across these regions over a 10-year period (2007-2016), using a standard scientometric approach. Research activity was compared with the countries' wealth and with the disease burden from different cancers, and analyses were also performed by the research domain (e.g. fundamental cancer biology, surgery). We found that although there was a correlation between outputs and national wealth, there were many outliers; the CEE countries publishing relatively more, and the R-CA, less. Outputs reflected cancer burdens, but there was a relative paucity of research on lung, colorectal, gastric and pancreatic cancer, as well as research domains such as screening and palliative care. Clinical trials accounted for only 3% of all research outputs from all countries, and were very international, with on average 1.5 CEE countries and 8.0 others involved in each article, and they were heavily cited (on average, 84 times in 5 years). Poland was by far the most research-active country, but significant needs and opportunities have been identified to expand the cancer research activity in all CEE and R-CA countries to enhance national cancer control planning.

[1]  S. Jungbluth,et al.  Europe combating cancer: The European Union's commitment to cancer research in the 6th Framework Programme , 2007, Molecular oncology.

[2]  Sameer Kumar,et al.  The contribution of ethnic groups to Malaysian scientific output, 1982–2014, and the effects of the new economic policy , 2016, Scientometrics.

[3]  A. L. Bosch,et al.  Improvement of European Translational Cancer Research. Collaboration between Comprehensive Cancer Centers , 2008 .

[4]  A. Jemal,et al.  Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. , 2012, The Lancet. Oncology.

[5]  Keith Pavitt,et al.  THE INEVITABLE LIMITS OF EU R&D FUNDING , 1998 .

[6]  David J. Currie,et al.  Big Science vs. Little Science: How Scientific Impact Scales with Funding , 2013, PloS one.

[7]  B. Sikic,et al.  Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement. , 2016, The oncologist.

[8]  H. Varmus,et al.  Accelerating progress on non-communicable diseases , 2013, The Lancet.

[9]  R. Sullivan,et al.  How may clinical research improve healthcare outcomes? , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  G. Lewison,et al.  Mapping the European cancer research landscape: An evidence base for national and Pan-European research and funding. , 2018, European journal of cancer.

[11]  Enrico Grande,et al.  The cure of cancer: a European perspective. , 2009, European journal of cancer.

[12]  M. Coleman,et al.  Responding to the challenge of cancer in Europe. , 2008 .

[13]  J. Borrás,et al.  Improving cancer control in the European Union: conclusions from the Lisbon round-table under the Portuguese EU Presidency, 2007. , 2008, European journal of cancer.

[14]  C. la Vecchia,et al.  Cancer Control in Central and Eastern Europe , 2016, The oncologist.

[15]  G. Lewison,et al.  Mapping the emergence and development of translational cancer research. , 2006, European journal of cancer.

[16]  Mark P. Carpenter,et al.  International Research Collaboration , 1979 .

[17]  Ismael Rafols,et al.  Global maps of science based on the new Web-of-Science categories , 2012, Scientometrics.

[18]  A. Znaor,et al.  Insights into cancer surveillance in Central and Eastern Europe, Israel and Turkey. , 2015, European journal of cancer care.

[19]  Ross Upshur,et al.  Evidence-based health policy: context and utilisation. , 2004, Social science & medicine.

[20]  Grant Lewison,et al.  Lung cancer researchers, 2008–2013: their sex and ethnicity , 2015, Scientometrics.

[21]  P. Butow,et al.  Beyond scientific rigour: funding cancer research of public value. , 2007, Health policy.

[22]  Grant Lewison,et al.  The State of Lung Cancer Research: A Global Analysis , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  C. la Vecchia,et al.  Potential for improvement in cancer management: reducing mortality in the European Union. , 2015, The oncologist.

[24]  J. Hoekman,et al.  The Geographical Distribution of Leadership in Globalized Clinical Trials , 2012, PloS one.

[25]  J. Coebergh,et al.  Cancer incidence and mortality patterns in South Eastern Europe in the last decade: gaps persist compared with the rest of Europe. , 2013, European journal of cancer.

[26]  Françoise Meunier,et al.  How can innovative forms of clinical research contribute to deliver affordable cancer care in an evolving health care environment? , 2013, European journal of cancer.

[27]  E. Steliarova-Foucher,et al.  Cancer registration in developing countries: luxury or necessity? , 2008, The Lancet. Oncology.